Profile data is unavailable for this security.
About the company
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
- Revenue in USD (TTM)42.31bn
- Net income in USD7.27bn
- Incorporated1900
- Employees109.00k
- LocationAbbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com/
More ▼
Mergers & acquisitions
| Acquired company | ABT:NYQ since announced | Transaction value |
|---|---|---|
| Walk Vascular LLC | -1.19% | -- |
Data delayed at least 15 minutes, as of Nov 26 2021 18:10 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Align Technology, Inc. | 3.76bn | 740.05m | 50.01bn | 18.07k | 68.27 | 14.22 | 59.26 | 13.31 | 9.29 | 9.29 | 47.15 | 44.60 | 0.7463 | 5.78 | 5.07 | 207,858.60 | 14.71 | 29.32 | 20.69 | 42.44 | 74.58 | 73.28 | 19.70 | 33.47 | 1.26 | -- | 0.00 | 0.00 | 2.71 | 23.93 | 301.08 | 65.27 | 23.72 | -- |
| Boston Scientific Corporation | 11.47bn | 1.10bn | 54.96bn | 38.00k | 50.22 | 3.34 | 25.06 | 4.79 | 0.768 | 0.768 | 8.01 | 11.55 | 0.3657 | 2.47 | 7.02 | 301,842.10 | 3.69 | 3.03 | 4.18 | 3.78 | 66.96 | 69.70 | 10.09 | 7.17 | 1.15 | -- | 0.3556 | 0.00 | -7.66 | 5.80 | -119.23 | -- | 0.3484 | -- |
| DexCom, Inc. | 2.32bn | 529.30m | 57.37bn | 5.50k | 111.28 | 26.85 | 92.60 | 24.74 | 5.32 | 5.32 | 23.26 | 22.04 | 0.5388 | 2.54 | 5.16 | 421,672.70 | 12.30 | 5.78 | 14.37 | 6.78 | 69.77 | 66.09 | 22.82 | 7.98 | 4.50 | 3.86 | 0.4519 | 0.00 | 30.54 | 36.81 | 388.23 | -- | 42.98 | -- |
| Edwards Lifesciences Corp | 5.09bn | 1.48bn | 68.38bn | 14.90k | 46.93 | 12.34 | 42.43 | 13.42 | 2.33 | 2.33 | 8.04 | 8.88 | 0.681 | 1.64 | 8.86 | 341,912.80 | 19.75 | 14.69 | 22.47 | 17.48 | 75.74 | 74.51 | 29.00 | 21.52 | 2.87 | -- | 0.097 | 0.00 | 0.8809 | 11.96 | -21.56 | 10.72 | 30.77 | -- |
| Becton Dickinson and Co | 20.25bn | 2.00bn | 69.61bn | 75.00k | 35.79 | 2.94 | 16.29 | 3.44 | 6.85 | 6.85 | 69.36 | 83.23 | 0.3754 | 3.86 | 8.27 | 269,960.00 | 3.88 | 2.61 | 4.39 | 2.96 | 46.56 | 46.63 | 10.33 | 7.49 | 0.9013 | 7.02 | 0.4265 | 72.79 | 18.29 | 10.16 | 161.02 | 15.45 | 11.39 | 4.69 |
| Stryker Corporation | 16.67bn | 1.90bn | 91.82bn | 43.00k | 48.95 | 6.48 | 31.94 | 5.51 | 4.97 | 4.97 | 43.64 | 37.59 | 0.5018 | 1.81 | 6.36 | 387,651.20 | 5.72 | 7.32 | 6.63 | 8.72 | 62.65 | 65.69 | 11.40 | 13.78 | 1.35 | -- | 0.4715 | 39.73 | -3.58 | 7.61 | -23.24 | 2.13 | 12.52 | 10.76 |
| Intuitive Surgical, Inc. | 5.49bn | 1.69bn | 117.53bn | 8.08k | 71.09 | 10.31 | 57.66 | 21.41 | 4.63 | 4.63 | 15.05 | 31.95 | 0.4661 | 2.72 | 8.55 | 679,185.80 | 14.51 | 13.99 | 15.86 | 15.59 | 69.12 | 68.84 | 31.14 | 28.80 | 5.01 | -- | 0.00 | 0.00 | -2.68 | 12.82 | -23.11 | 12.49 | 33.35 | -- |
| Medtronic PLC | 31.80bn | 4.70bn | 149.35bn | 90.00k | 31.98 | 2.87 | 20.07 | 4.70 | 3.47 | 3.47 | 23.49 | 38.66 | 0.3389 | 2.32 | 5.87 | 353,300.00 | 5.04 | 4.77 | 5.65 | 5.36 | 67.71 | 68.51 | 14.88 | 14.96 | 2.36 | 15.57 | 0.3294 | 60.93 | 4.16 | 0.8752 | -25.94 | -0.2157 | 5.31 | 8.83 |
| Abbott Laboratories | 42.31bn | 7.27bn | 222.59bn | 109.00k | 31.02 | 6.47 | 20.64 | 5.26 | 4.06 | 4.05 | 23.62 | 19.47 | 0.5924 | 3.50 | 7.02 | 388,146.80 | 10.17 | 4.19 | 12.18 | 4.91 | 56.90 | 57.11 | 17.17 | 9.25 | 1.42 | 17.26 | 0.3469 | 78.93 | 8.48 | 11.14 | 24.88 | 11.53 | 14.42 | 8.45 |
| Thermo Fisher Scientific Inc. | 39.06bn | 8.57bn | 251.69bn | 80.00k | 29.63 | 6.50 | 22.72 | 6.44 | 21.55 | 21.55 | 98.32 | 98.24 | 0.5675 | 4.38 | 6.38 | 488,237.50 | 12.44 | 6.46 | 13.85 | 7.31 | 51.05 | 46.15 | 21.93 | 14.50 | 2.56 | 21.83 | 0.3593 | 7.98 | 26.14 | 13.69 | 72.11 | 26.34 | 28.37 | 7.21 |
Data as of Nov 26 2021. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD
31.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2021 | 141.36m | 7.97% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2021 | 84.45m | 4.76% |
| BlackRock Fund Advisorsas of 30 Sep 2021 | 82.69m | 4.66% |
| SSgA Funds Management, Inc.as of 30 Sep 2021 | 72.43m | 4.09% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2021 | 56.99m | 3.22% |
| Geode Capital Management LLCas of 30 Sep 2021 | 27.13m | 1.53% |
| Massachusetts Financial Services Co.as of 30 Sep 2021 | 26.62m | 1.50% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2021 | 25.57m | 1.44% |
| Polen Capital Management LLCas of 30 Sep 2021 | 22.01m | 1.24% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2021 | 19.76m | 1.11% |
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
